Focused DPEP-1 Inhibitor PlatformA concentrated platform focus (DPEP-1/LSALT Peptide) creates durable technical depth and repeatable R&D pathways across inflammatory indications. This reduces program dispersion, supports efficient resource allocation, and enhances appeal for long-term partnerships and licensing opportunities.

Monoclonal Antibody Program For Organ InjuryA complementary monoclonal antibody program targeting extracellular histones broadens the therapeutic portfolio and indication coverage. Structural diversification across modalities increases the firm's strategic optionality for collaborations, risk-sharing with partners, and multiple potential value-creating exit pathways.

Partnership/licensing-centric Business ModelAn explicit partnership/out-licensing model is a durable commercialization path for clinical-stage biotech: it allows capital-efficient development, milestone and royalty revenue potential, and risk transfer to larger pharma, preserving upside while limiting required in-house commercialization spend.

Bears Say

No TTM Revenue And Ongoing Net LossesZero trailing revenue and repeated net losses mean the company cannot self-fund development and must rely on external capital or deals. Over the medium term this increases dilution risk, constrains strategic choices, and limits bargaining power with potential partners or acquirers.

Persistent Negative Operating And Free Cash FlowConsistent negative operating and free cash flow point to ongoing cash burn that will require financing to sustain clinical programs. This creates execution risk for trials and program timelines, increases the frequency of dilution events, and pressures management to secure deals quickly.

Thin Balance Sheet And Material DebtNegative equity, small reported assets and material debt indicate elevated solvency and refinancing risk. Limited financial flexibility can hamper R&D continuity, reduce runway between financings, and weaken negotiating leverage in partner discussions or any restructuring scenarios.

Arch Biopartners News

Arch Biopartners publishes data linking cytokine IL-32 to inflammation, DKD

Arch Biopartners (ACHFF) announced that a scientific team led by Dr. Justin Chun at the University of Calgary...

29d ago

Arch Biopartners appoints Patrick Vink as chairman of the board

Arch Biopartners (ACHFF) announced the appointment of Dr. Patrick Vink as Chairman of the Company’s Board of Directors,...

2M ago

Arch granted ethics approval for St. Michaels participation in Phase II trial

Arch Biopartners (ACHFF) announced that the University Health Network Research Ethics Board has granted ethics approval for St....

3M ago

Arch Biopartners’ LSALT Peptide Study: A Promising Step in AKI Prevention

Arch Biopartners (($TSE:ARCH)) announced an update on their ongoing clinical study. Arch Biopartners is conducting a Phase 2...

4M ago

ARCH

ARCH FAQ

What was Arch Biopartners’s price range in the past 12 months?

Arch Biopartners lowest stock price was C$0.67 and its highest was C$1.95 in the past 12 months.

What is Arch Biopartners’s market cap?

Arch Biopartners’s market cap is C$53.55M.

When is Arch Biopartners’s upcoming earnings report date?

Arch Biopartners’s upcoming earnings report date is Jun 02, 2026 which is in 84 days.

How were Arch Biopartners’s earnings last quarter?

Currently, no data Available

Is Arch Biopartners overvalued?

According to Wall Street analysts Arch Biopartners’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Arch Biopartners pay dividends?

Arch Biopartners does not currently pay dividends.

What is Arch Biopartners’s EPS estimate?

Arch Biopartners’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Arch Biopartners have?

Arch Biopartners has 66,933,290 shares outstanding.

What happened to Arch Biopartners’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Arch Biopartners?

Currently, no hedge funds are holding shares in TSE:ARCH

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Arch Biopartners Stock Smart Score

Underperform

Insider Transactions

Sold Shares

Worth C$85.6K over
the Last 3 Months

Technicals

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-82.69%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Arch Biopartners

Arch Biopartners Inc., a biotechnology company, develops technologies for medical or commercial impact. It focuses on developing its lead drug candidate Metablok to treat or prevent dipeptidase-1 mediated organ inflammation in the lungs, liver, or kidneys, which results in organ damage or failure, including in the case of sepsis and COVID-19. The company also develops AB569, a drug candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds. In addition, it develops Borg, a peptide-solid surface interface to inhibit biofilm formation and reduce corrosion; and MetaMx, which are synthetic molecules that target brain tumor initiating cells and invasive glioma cells. The company is based in Toronto, Canada.